ClinicalTrials.gg
TerminatedNCT04152018Updated May 28, 2025

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

A Phase 1 interventional study of PF-06940434 and PF-06801591 in Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma and Ovarian Cancer, sponsored by Pfizer. Terminated at 31 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer — 3 open to participants now, 5 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Pfizer.

Enrollment
16th of 30
85 · median 105
Started
2019
with 3 others
Phase 1
19 of 30
3 open now
Registered
15th of 30
by date

Among the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer, this one is the 16th largest by enrollment, is one of 4 that started in 2019, is one of 19 in phase 1, and was the 15th registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

3 of the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer, or all of them as a file.
02

Study summary

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 3 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck
  • Renal Cell Carcinoma
  • Ovarian Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Lung Squamous Cell Carcinoma
  • Pancreatic Cancer
  • Bile Duct Cancer
  • Endometrial Cancer
  • Melanoma Cancer
  • Urothelial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of SCCHN, RCC (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer.

Part 2:

  • Arm A SCCHN:

    • Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx.
    • PDL-1 expression positive and CPS ≥1. No prior systemic therapy administered in the recurrent or setting (except for systemic therapy given as part of a multimodal treatment for locally advanced disease).
  • Arm B RCC (clear cell):

    • 1 or 2 including /PD-1 immunotherapy in combination or sequentially with antiangiogenic directed treatment
  • Adequate bone marrow, kidney and liver function.
  • Performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Participant disease status is suitable for local therapy administered with curative intent.
  • Hypertension that cannot be controlled by medications.
  • Active or prior disease
  • Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) , , and known infection or Acquired Immunodeficiency Syndrome-related illness
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Single Agent Dose Escalation

    Drug: PF-06940434

  • Experimental
    Dose Finding Anti-PD-1 Combination 1

    Part 1B PF-06940434 plus anti-PD-1

    Drug: PF-06940434 · Drug: PF-06801591

  • Experimental
    Dose Expansion Arm A

    PF-06940434 with anti-PD-1 in SCCHN

    Drug: PF-06940434 · Drug: PF-06801591

  • Experimental
    Dose Expansion Arm B

    PF-06940434 with anti-PD-1 in RCC

    Drug: PF-06940434 · Drug: PF-06801591

  • Experimental
    Dose Expansion, Arm C

    PF-06940434 with anti-PD-1 (both Q3W)

    Drug: PF-06940434 · Drug: PF-06801591

Interventions

  • DrugPF-06940434

    PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated

  • PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.

    Also known as: Anti-PD-1

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding

    Time frame: Baseline up to 28 Days (Cycle 1)

  2. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Time frame: Baseline up to approximately 24 months

  3. Number of Participants With Adverse Events (AEs) According to Severity

    Time frame: Baseline up to approximately 24 months

  4. Number of Participants With Adverse Events (AEs) According to Seriousness

    Time frame: Baseline up to up to approximately 24 months

  5. Number of Participants With Adverse Events (AEs) by Relationship

    Time frame: Baseline up to approximately 24 months

  6. Progression-Free Survival (PFS) for Dose Expansion

    The period from study entry until disease progression, death or date of last contact.

    Time frame: Baseline up to 24 Months

  7. Objective Response Rate - Percentage of Participants With Objective Response in Dose Expansion

    Time frame: Baseline up to 24 months

  8. Duration of Response (DR) for Dose Expansion

    Time frame: Baseline up to 24 Months

Secondary outcomes

  1. PF-06940434 after multiple doses PK parameters (Cmax).

    Maximum observed plasma concentration of PF-06940434.

    Time frame: Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).

  2. Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434.

    Time zero extrapolated to the last quantifiable time point prior to the next dose.

    Time frame: Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).

  3. Systemic Clearance (CL)

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).

  4. Volume of Distribution (Vd)

    Time frame: Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).

  5. Incidence and titers of anti-drug antibodies (ADA) against PF-06940434.

    Time frame: Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).

  6. Incidence and titers of neutralizing antibodies (NAb) against PF-06940434.

    Titers of neutralizing antibodies (NAb) against PF-06940434.

    Time frame: Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).

  7. PK parameters of PF-06940434 and PF-06801591 (Cmax).

    Maximum observed plasma concentration after multiple doses of PF-06940434 and PD-1 (PF-06801591).

    Time frame: Pre-dose on Cycle 1 Day 1 and on day 15 of Cycle 1; Day 1 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days)

  8. Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434 and PF-06801591.

    Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434 and PF-06801591.

    Time frame: Pre-dose on Cycle 1 Day 1 and on day 15 of Cycle 1; Day 1 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days)

  9. Characterize the multiple dose PK of PF-06940434 following intravenous administration in combination with PF-06801591.

    Maximum observed plasma concentration of PF-06940434.

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  10. Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434.

    Time zero extrapolated to the last quantifiable time point prior to the next dose.

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  11. Number of participants with increased T-cells after PF-06940434 treatment.

    Time frame: Pre-dose on Day 1 of Cycle 1; pre-dose on Day 1 of Cycles 2 and 3 (each cycle is 28 days)

  12. Progression-Free Survival (PFS) for Dose Expansion

    The period from study entry until disease progression, death or date of last contact.

    Time frame: Baseline to measured progression (up to approximately 24 months)

  13. Duration of Response (DR)

    Time frame: Baseline up to approximately 24 Months

  14. Number of Participants With Objective Response for Dose Expansion portion

    Time frame: Baseline up to 24 months

  15. Disease Control Rate (DCR)

    DCR is defined as the percent of participants with a confirmed complete response (CR), partial response (PR) or stable disease (SD) according to RECIST 1.1.

    Time frame: Every 8 weeks from the time of enrollment up to 2 years

  16. Trough concentrations of PF-06940434 and PF-06801591 in Dose Expansion

    Time frame: Day 1 of Cycle 1 though 4, Day 1 of every 2 Cycles starting from Cycle 5 up to 24 months (each cycle is 28 days). For Part 2 Cohort 3, Day 1 of Every Cycle (each cycle is 21 days)

  17. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days]

  18. Incidence and titers of anti-drug antibodies (ADA) against PF-06801591 in Dose Finding and Dose Expansion

    Incidence and titers of anti-drug antibodies (ADA) against PF-06801591.

    Time frame: Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days].

  19. Incidence and titers of neutralizing antibodies (NAb) against PF-06801591 in Dose Finding and Dose Expansion.

    Incidence and titers of neutralizing antibodies (NAb) against PF-06801591.

    Time frame: Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days].

  20. Overall Survival

    The period from study entry until death or date of last contact (24 months)

    Time frame: From baseline to up to 2 years after last dose of study drug

07

Study locations

31 sites
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • HonorHealth Scottsdale Shea Medical Center
    Scottsdale, Arizona 85260, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • UCLA Hematology Oncology
    Los Angeles, California 90095, United States
  • UCLA Hematology/Oncology
    Santa Monica, California 90404, United States
  • Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
  • Siteman Cancer Center - West County
    Creve Coeur, Missouri 63141, United States
  • Siteman Cancer Center - North County
    Florissant, Missouri 63031, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center - South County
    Saint Louis, Missouri 63129, United States
  • Siteman Cancer Center - St. Peters
    Saint Peters, Missouri 63376, United States
  • Duke Univ. Medical Center/Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Investigational Chemotherapy Service
    Durham, North Carolina 27710, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Southern Medical Day Care Centre
    Wollongong, New South Wales 2500, Australia
  • Asan Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 05505, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Onkologicky ustav sv. Alzbety, s.r.o.
    Bratislava, 812 50, Slovakia
  • Univerzitna nemocnica Bratislava
    Bratislava, 82101, Slovakia
  • Narodny ustav srdcovych a cievnych chorob, a.s.
    Bratislava, 833 48, Slovakia
  • MR Poprad s.r.o.
    Komárno, 945 01, Slovakia
  • KARDIO, s.r.o.
    Poprad, 058 01, Slovakia
  • POKO Poprad, s.r.o., Ambulancia klinickej onkologie
    Poprad, 058 01, Slovakia
  • Nemocnica Poprad a.s.
    Poprad, 058 45, Slovakia
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Dec 2024, 60 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2019
First posted
Nov 5, 2019
StartActual
Nov 13, 2019
Primary completionActual
Dec 10, 2024
CompletionActual
Dec 10, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04152018
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 5, 2019
Start date
Nov 13, 2019
Primary completion
Dec 10, 2024
Completion
Dec 10, 2024
Last update
May 28, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion